Valion Bio, Inc. Lease, Cost
Valion Bio, Inc. (VBIO) reported Lease, Cost of $535.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-14
- Valion Bio, Inc. lease, cost for the quarter ending 2026-06-30 was $535.00K, a 4763.64% increase year-over-year.
- Valion Bio, Inc. lease, cost for the quarter ending 2026-03-31 was $485.00K, a 12025.00% increase year-over-year.
- Valion Bio, Inc. lease, cost for the quarter ending 2025-06-30 was $11.00K.
- Valion Bio, Inc. lease, cost for the quarter ending 2025-03-31 was $4.00K.
- Valion Bio, Inc. lease, cost for fiscal 2025 was $16.00K, a 86.44% decline from fiscal 2024.
- Valion Bio, Inc. lease, cost for fiscal 2024 was $118.00K, a 46.85% decline from fiscal 2023.
- Valion Bio, Inc. lease, cost for fiscal 2023 was $222.00K, a 0.45% decline from fiscal 2022.
- Valion Bio, Inc. lease, cost for fiscal 2022 was $223.00K, a 355.10% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 12 month |
|---|---|---|---|
| 2026-06-30 | $535.00K 10-Q · filed 2026-08-14 | $1.02M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $485.00K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $16.00K 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $11.00K 10-Q · filed 2026-08-14 | $15.00K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $118.00K 10-K · filed 2026-03-30 | ||
| 2023-12-31 | $222.00K 10-K · filed 2025-03-21 | ||
| 2022-12-31 | $223.00K 10-K · filed 2024-03-25 | ||
| 2022-06-30 | $57.00K 10-Q · filed 2022-08-15 | $112.00K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $55.00K 10-Q · filed 2022-05-16 | ||
| 2021-12-31 | $49.00K 10-K · filed 2023-03-31 | ||
| 2021-06-30 | $3.00K 10-Q · filed 2022-08-15 | $9.00K 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $6.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |